** Shares of Roivant Sciences ROIV.O fall 2.2% to $12.20 before the bell
** Co says its experimental lung disease drug, namilumab, did not meet the main and secondary goals in a mid-stage study
** Co was testing namilumab in patients with chronic active pulmonary sarcoidosis, a condition in which lumps of inflammatory cells form in the lungs
** Adds that it will stop further development of the drug to treat sarcoidosis
** As of last close, ROIV up 11% YTD
(Reporting by Bhanvi Satija in Bengaluru)
((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。